International registry on the use of the CytoSorb® adsorber in ICU patients

Friesecke, Sigrun; Träger, Karl; Schittek, Gregor Alexander; Molnár, Zsolt; Bach, Friedhelm; Kogelmann, Klaus; Bogdanski, Ralph; Weyland, A.; Nierhaus, Axel; Nestler, Frieder; Olboeter, Detlef; Tomescu, Dana; Jacob, David; Haake, Hendrik; Grigoryev, Evgeny; Nitsch, Markus; Baumann, Arnd; Quintel, Michael; Schott, M.; Kielstein, JT; Meier‐Hellmann, Andreas; Born, F.; Schumacher, Ulrike; Singer, Mervyn; Kellum, John; Brunkhorst, Frank M.

doi:10.1007/s00063-017-0342-5

Cited by 100 publications

(97 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…With regard to the treatment of sepsis, clinical trials are lacking at present, and what we have are mainly small case series [14][15][16][17]. There is also an international CytoSorb Registry, and recent data analysis on 198 patients indicate that observed mortality (65%) was substantially better compared to predicted (mean of 81%), and treatment was also shown to be safe [18].…”

Section: Introductionmentioning

confidence: 94%

Extracorporeal cytokine adsorption in septic shock: A proof of concept randomized, controlled pilot study

Hawchar

László

Öveges

et al. 2019

Journal of Critical Care

153

164

View full text Add to dashboard Cite

Background: The aim of this proof of concept, prospective, randomized pilot trial was to investigate the effects of extracorporeal cytokine removal (CytoSorb®) applied as a standalone treatment in patients with septic shock. Methods: 20 patients with early (b24 h) onset of septic shock of medical origin, on mechanical ventilation, norepinephrineN10 μg/min, procalcitonin (PCT) N 3 ng/mL without the need for renal replacement therapy were randomized into CytoSorb (n = 10) and Control groups (n = 10). CytoSorb therapy lasted for 24 h. Clinical and laboratory data were recorded at baseline (T 0), T 12 , T 24 , and T 48 hours. Results: Overall SOFA scores did not differ between the groups. In the CytoSorb-group norepinephrine requirements and PCT concentration decreased significantly

show abstract

Section: Introductionmentioning

confidence: 94%

Extracorporeal cytokine adsorption in septic shock: A proof of concept randomized, controlled pilot study

Hawchar

László

Öveges

et al. 2019

Journal of Critical Care

153

164

View full text Add to dashboard Cite

show abstract

“…Its goal is to track patient mortality (primary endpoint) and secondary outcomes such as hospital-and intensive care unit-length of stay, vasopressor use, renal replacement therapy, and end-organ function. Multicenter data from 198 patients (68% of whom had sepsis with a mean APACHE II score of 33.1) were analyzed in the registry's third interim analysis and reported in 2017 [133]. Serum IL-6 levels following CytoSorb therapy were markedly decreased and the reported mortality with this therapy was 65% (compared to 78% predicted by their APACHE II score).…”

Section: The Future Of Cytokine Adsorption Therapymentioning

confidence: 99%

Clinical Utility of Extracorporeal Cytokine Hemoadsorption Therapy: A Literature Review

et al. 2018

View full text Add to dashboard Cite

Cytokines play a critical role in coordinating and amplifying a host immune response to infection. The normal pattern of localized and systemic release of proinflammatory and anti-inflammatory cytokines varies on the basis of the disease process. A dysregulated cytokine response can lead to a hyper-inflammatory condition called a cytokine storm. This is believed to contribute to the pathophysiology of sepsis and septic shock, a condition carrying high morbidity and mortality in critically ill patients. Extracorporeal cytokine hemoadsorption is an emerging technology utilized in the treatment of dysregulated inflammatory states such as sepsis, although there is a paucity of clinical evidence supporting its outcomes benefits. We assess the peer-reviewed literature relating to cytokine hemoadsorption in the context of sepsis and suggest areas of future research incorporating this novel technology.

show abstract

“…This webbased registry aims to record all relevant information (e. g., diagnosis, comorbidities, treatment/concomitant medication, clinical laboratory parameters, outcome) during treatments with CytoSorb (ClinicalTrials.gov Identifier: NCT02312024) [13]. The primary endpoint of this prospective, multicenter registry involving more than 130 centers from 22 countries was to compare the in-hospital mortality with that predicted according to APACHE II and SAPS II score.…”

Section: Ebpts and Database Registriesmentioning

confidence: 99%

“…Interestingly, the observed population is not limited to septic patients but instead it expanded to patients with cardiac surgery and cardiopulmonary bypass, those preemptively treated with CytoSorb in the operating room or postoperatively in the ICU or those with liver failure, acute pancreatitis, trauma, burns, or acute respiratory distress syndrome. Preliminary data are available from the first 198 patients [13]. This project aims to design and nationally promote a web-based registry specifically designed for oXiris membrane (Baxter, Meyzieu, France).…”

Section: Ebpts and Database Registriesmentioning

confidence: 99%

oXirisNet Registry: A Prospective, National Registry on the oXiris Membrane

Villa¹,

Rosa²,

Samoni³

et al. 2019

Blood Purif

View full text Add to dashboard Cite

Worldwide, the widespread use of extracorporeal blood purification therapies (EBPTs) is progressively increasing in everyday clinical practice, particularly in critical care settings. The efficacy of EBPTs on removal of inflammatory mediators is already well established in the literature. Nonetheless, clinical research is particularly cumbersome in this setting, and many clinical trials aiming at exploring the effect of EBPTs on outcomes have failed in demonstrating consistent results regarding 28-day- or hospital-mortality rates. In recent years, data emerging from large registries have been increasingly used to provide real-world evidence on the effectiveness, quality, and safety of EBPTs. The philosophy behind this Italian Registry is a renewal of the concept of “clinical research” in the field of EBPTs applied to critically ill, septic patients with or without acute kidney injury. The platform used for the registry – specifically designed for research purposes and fed by clinical data prospectively observed – promotes good practice with a positive and active interaction with the physician/researcher. This interaction has favorable real-time effects for the specific patient, providing “bed-side clinical feedbacks,” similarly to the decision support system. Examples of these issues are bundles reminders, suggestions for drug adjustment according to the extracorporeal clearance, clinical calculator for body mass index, or mechanical ventilation setting. The platform-physician interaction has additional useful effects on the single utilizing center, providing “mid-term, center-specific clinical feedbacks.” These generally consist of clusters of data taken over a certain period, for example, regarding patients’ outcome, microbiological data, or use of disposable for EBPTs.

show abstract

International registry on the use of the CytoSorb® adsorber in ICU patients

Cited by 100 publications

References 16 publications

Extracorporeal cytokine adsorption in septic shock: A proof of concept randomized, controlled pilot study

Extracorporeal cytokine adsorption in septic shock: A proof of concept randomized, controlled pilot study

Clinical Utility of Extracorporeal Cytokine Hemoadsorption Therapy: A Literature Review

oXirisNet Registry: A Prospective, National Registry on the oXiris Membrane

Contact Info

Product

Resources

About